Date: 2015-05-05
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Celyad previously known as Cardio3 Biosciences (Belgium)
Therapeutic area: Cardiovascular diseases - Regenerative medicine
Type agreement: name change
Action mechanism:
Disease:
Details: * On May 5, 2015, Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, announced that the Company’s proposed name change to “Celyad” is now confirmed, effective immediately. * On April 15, 2015, Cardio3 BioSciences announced its intention to change its corporate name to “Celyad”. The company plans to use the new name for commercial purposes effective immediately; the company will seek shareholder approval of the new name for the legal entity at the annual general meeting of shareholders scheduled for May 5, 2015. The Company’s ticker symbol will change from CARD to CYAD immediately following shareholder approval of the name change.
Financial terms:
Latest news:
